The lactose-synthase complex contains one catalytic galactosyltransferase and one regulatory alpha-lactalbumin subunit. Alpha-lactalbumin favors glucose recognition, enabling lactose production. The linked structures provide ortholog mechanistic evidence; their components are not both human.

Human wild-type kinetic measurements favor the 1,2-1,6-arm GlcNAc acceptor over the other tested N-glycan branches and chitotriose. Structures of the human M340H construct explain this branch preference; the abstract distinguishes these mutant structures from the wild-type kinetics.

Transcript comparisons and F9-cell transfection support preferential surface targeting of the longer initiation product and predominant Golgi residence of the shorter product in the examined systems. These results do not establish exclusive compartments for human products.

Mutagenesis of a recombinant human galactosyltransferase fusion implicates Tyr284, Tyr309 and Trp310 in recognition of GlcNAc, with Tyr309 also affecting UDP-galactose recognition. The available abstract is explicitly truncated; bacterial secretion of the fusion is not evidence for native human secretion.

Co-expression of human B4GALT1 with IgG in HEK cells increased Fc N-glycan galactosylation. The inspected Results report an optimum at a low enzyme-vector fraction, while the expression Methods identify the human B4GALT1 construct.

Purified soluble human galactosyltransferase preparations were catalytically active with free GlcNAc and glycoprotein acceptors, and with glucose when alpha-lactalbumin was present. These assays support the three retained catalytic activities.

Active soluble enzyme was isolated from human milk, amniotic fluid and malignant ascites. The abstract establishes its presence in those fluids, without determining the route by which it arrived in each.

The p.Asn352Ser hypomorph has reduced galactosyltransferase activity and is associated with reduced serum glycoprotein galactosylation/sialylation and lower LDL cholesterol and fibrinogen concentrations; the specific causal routes remain unresolved by the abstract.

Immunoelectron microscopy of human duodenal enterocytes detected galactosyltransferase at the cell surface, with strong brush-border and lateral-interdigitation labeling and preferential extracellular orientation. An adhesion function was suggested rather than demonstrated.

Immunoelectron microscopy in HeLa cells localized galactosyltransferase to two or three trans-Golgi cisternae, overlapping the thiamine-pyrophosphatase distribution. This is localization evidence in the examined cells, not an exclusive compartment assignment across all systems.

Transmembrane Cys29/His32 substitutions disrupted galactosyltransferase homodimerization and reduced Golgi retention. Co-immunoprecipitation detected association with tubulins, suggesting a cytoskeletal contribution without independently establishing that contribution or a universal oligomeric state.

Deep-research synthesis: core function is Golgi (trans-Golgi) beta-1,4-galactosylation of terminal GlcNAc to form LacNAc on N-glycans/glycolipids, with Mn2+ cofactor and UDP-Gal donor; lactose synthase (with LALBA) is a tissue-specific core function; reported cancer/apoptosis/inflammation roles are pleiotropic, context-specific consequences of altered glycosylation and not dedicated B4GALT1 processes.

Human GalT constructs form Golgi-localized homomeric associations and associate with SiaT in live-cell complementation experiments.

The reviewed record explicitly identifies manganese as cofactor and places both initiation products in Golgi membranes.